Literature DB >> 18064064

No changes in densities of cannabinoid receptors in the superior temporal gyrus in schizophrenia.

Chao Deng1, Mei Han, Xu-Feng Huang.   

Abstract

OBJECTIVE: In recent years, abnormal changes in the endocannabinoid system have been found in schizophrenia. The superior temporal gyrus (STG) is strongly implicated in the pathophysiology of schizophrenia, particularly with regards to auditory hallucinations. In this study, we investigated the binding density of cannabinoid CB1 receptors in the STG of schizophrenia patients compared to control subjects.
METHODS: Quantitative autoradiography was used to investigate the binding densities of [(3)H]SR141716A (a selective antagonist) and [(3)H]CP-55940 (an agonist) to the CB1 receptors in the STG. Post-mortem brain tissue was obtained from the NSW Tissue Resource Centre (Australia).
RESULTS: Contrasting to previous findings in the alterations of CB1 receptor densities in the prefrontal, anterior and posterior cingulate cortex of schizophrenia, which were suggested to be associated to impairment of cognition function, no significant difference was found between the schizophrenia and control cases in both [(3)H]SR141716A and [(3)H]CP-55940 binding.
CONCLUSION: We suggest that CB1 receptors in the STG are not involved in the pathology of schizophrenia and the auditory hallucination symptom of this disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18064064      PMCID: PMC5550648          DOI: 10.1007/s12264-007-0051-9

Source DB:  PubMed          Journal:  Neurosci Bull        ISSN: 1995-8218            Impact factor:   5.203


  26 in total

1.  Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia.

Authors:  Kelly A Newell; Chao Deng; Xu-Feng Huang
Journal:  Exp Brain Res       Date:  2006-05-19       Impact factor: 1.972

Review 2.  New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia.

Authors:  Hiroshi Ujike; Yukitaka Morita
Journal:  J Pharmacol Sci       Date:  2004-12       Impact factor: 3.337

Review 3.  Cannabinoid-1 receptor: a novel target for the treatment of neuropsychiatric disorders.

Authors:  K Yaragudri Vinod; Basalingappa L Hungund
Journal:  Expert Opin Ther Targets       Date:  2006-04       Impact factor: 6.902

Review 4.  Psychiatric effects of cannabis.

Authors:  A Johns
Journal:  Br J Psychiatry       Date:  2001-02       Impact factor: 9.319

5.  Clozapine decreases [3H] CP 55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens.

Authors:  Suresh Sundram; David Copolov; Brian Dean
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-07-02       Impact factor: 3.000

6.  Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use.

Authors:  B Dean; S Sundram; R Bradbury; E Scarr; D Copolov
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

7.  Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia.

Authors:  Kelly A Newell; Katerina Zavitsanou; Stephen Kum Jew; Xu-Feng Huang
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2006-08-09       Impact factor: 5.067

8.  A functional neuroanatomy of hallucinations in schizophrenia.

Authors:  D A Silbersweig; E Stern; C Frith; C Cahill; A Holmes; S Grootoonk; J Seaward; P McKenna; S E Chua; L Schnorr
Journal:  Nature       Date:  1995-11-09       Impact factor: 49.962

9.  Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study.

Authors:  A Oviedo; J Glowa; M Herkenham
Journal:  Brain Res       Date:  1993-07-09       Impact factor: 3.252

10.  Kraepelin revisited: a reassessment and statistical analysis of dementia praecox and manic-depressive insanity in 1908.

Authors:  A Jablensky; H Hugler; M Von Cranach; K Kalinov
Journal:  Psychol Med       Date:  1993-11       Impact factor: 7.723

View more
  12 in total

1.  Reduced Brain Cannabinoid Receptor Availability in Schizophrenia.

Authors:  Mohini Ranganathan; Jose Cortes-Briones; Rajiv Radhakrishnan; Halle Thurnauer; Beata Planeta; Patrick Skosnik; Hong Gao; David Labaree; Alexander Neumeister; Brian Pittman; Toral Surti; Yiyun Huang; Richard E Carson; Deepak Cyril D'Souza
Journal:  Biol Psychiatry       Date:  2015-08-29       Impact factor: 13.382

2.  Social isolation and chronic handling alter endocannabinoid signaling and behavioral reactivity to context in adult rats.

Authors:  N R Sciolino; M Bortolato; S A Eisenstein; J Fu; F Oveisi; A G Hohmann; D Piomelli
Journal:  Neuroscience       Date:  2010-04-13       Impact factor: 3.590

3.  Cannabinoid CB1 receptor immunoreactivity in the prefrontal cortex: Comparison of schizophrenia and major depressive disorder.

Authors:  Stephen M Eggan; Samuel R Stoyak; Christopher D Verrico; David A Lewis
Journal:  Neuropsychopharmacology       Date:  2010-06-16       Impact factor: 7.853

4.  Paranoid schizophrenia is characterized by increased CB1 receptor binding in the dorsolateral prefrontal cortex.

Authors:  Victoria S Dalton; Leonora E Long; Cyndi Shannon Weickert; Katerina Zavitsanou
Journal:  Neuropsychopharmacology       Date:  2011-04-06       Impact factor: 7.853

5.  Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia.

Authors:  Kimberly J Jenko; Jussi Hirvonen; Ioline D Henter; Kacey B Anderson; Sami S Zoghbi; Thomas M Hyde; Amy Deep-Soboslay; Robert B Innis; Joel E Kleinman
Journal:  Schizophr Res       Date:  2012-08-19       Impact factor: 4.939

6.  Immunodensity and mRNA expression of A2A adenosine, D2 dopamine, and CB1 cannabinoid receptors in postmortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment.

Authors:  Leyre Urigüen; M Julia García-Fuster; Luis F Callado; Benito Morentin; Romano La Harpe; Vicent Casadó; Carmen Lluis; Rafael Franco; Jesús A García-Sevilla; J Javier Meana
Journal:  Psychopharmacology (Berl)       Date:  2009-08-04       Impact factor: 4.530

Review 7.  Effects of cannabis use on human brain structure in psychosis: a systematic review combining in vivo structural neuroimaging and post mortem studies.

Authors:  Charlotte Rapp; Hilal Bugra; Anita Riecher-Rössler; Corinne Tamagni; Stefan Borgwardt
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

8.  Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects.

Authors:  Eva M Marco; María S García-Gutiérrez; Francisco-Javier Bermúdez-Silva; Fabricio A Moreira; Francisco Guimarães; Jorge Manzanares; María-Paz Viveros
Journal:  Front Behav Neurosci       Date:  2011-10-05       Impact factor: 3.558

9.  Distinct neurobehavioural effects of cannabidiol in transmembrane domain neuregulin 1 mutant mice.

Authors:  Leonora E Long; Rose Chesworth; Xu-Feng Huang; Alexander Wong; Adena Spiro; Iain S McGregor; Jonathon C Arnold; Tim Karl
Journal:  PLoS One       Date:  2012-04-03       Impact factor: 3.240

Review 10.  Endocannabinoid system in psychotic and mood disorders, a review of human studies.

Authors:  Ranjini Garani; Jeremy J Watts; Romina Mizrahi
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2020-09-06       Impact factor: 5.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.